Microsoft word - a. anaesthesia.doc



Regis (Gigi) Park, Research Chair, Board of Directors
Surgery is a stressful experience. For a patient with mast cell disease, that stress is compounded by the possibility of
complications including anaphylaxis, cardiovascular collapse, increased bleeding and even death. Therefore, general
anesthesia is considered a high-risk procedure in patients with mast cell disease. It is critical that all members of the
patient’s operating team take proper precautions before, during, and after surgery to protect against potentially life-
threatening mast cell activation.
It is imperative that good communication is established between the patient, referring physician, surgeon,
anesthesiologist, nurses, and all others involved in the patient’s care before, during, and after surgery. The surgeon
must be aware of the patient’s mast cell disease and inform themselves of the measures necessary to keep the patient
as free of symptoms as possible. Additionally, the patient should contact the anesthesiologist assigned to their care as
soon as possible after surgery has been scheduled. Both regional and general anesthetics can cause life-threatening
complications. An experienced anesthesiologist is aware of medications known to cause mast cell degranulation and
medications that stabilize mast cells. If the patient is satisfied that their anesthesiologist fully understands the importance
of planning around the mast cell disease, it will go a long way toward calming the patient, which in turn may reduce mast
cell mediator release.

Symptoms should be as well-controlled as possible in the days prior to surgery. The patient should carefully avoid
known triggers of mast cell activity and should take their medications as prescribed. Those medications include H1 and
H2 histamine receptor blockers such as Allegra (H1) and Zantac (H2). A mast cell stabilizer such as disodium
cromoglycate or ketotifen, and medications targeting other mast cell mediators should be taken regularly if they are part
of the patient’s normal drug regimen.
The patient’s complete medication list should be reviewed by the surgical team prior to surgery and any necessary
medication changes should be thoroughly discussed with the patient. For example, if the patient regularly takes a
medication in the family known as beta blockers for blood pressure or heart rate abnormality, a change to another drug
should be considered well before surgery is scheduled. Beta blockers are generally avoided in people with mast cell
disease undergoing surgery because they interfere with an important natural control of mast cell activation. These drugs
may also interfere with the use of epinephrine, which may be required if the patient has a major release of mast cell
mediators resulting in low blood pressure during surgery. Other drugs that may interfere with control of blood pressure
during surgery must be carefully reviewed by the patient’s physician before the surgery.
It may be necessary to perform a “graded challenge” procedure in the hospital under the supervision of an allergist and
an anesthesiologist for certain medications if there is no history of exposure to that medication. This procedure usually
starts with scratching the skin with a small amount of medication followed by injection of increasing amounts with careful
monitoring after each injection. Resuscitation equipment and drugs including epinephrine must be readily available
during the procedure.

For pre-operative control of anxiety and the reduction of mast cell activity, drugs in the valium family (diazepam,
midazolam, lorazepam) are usually effective. Some procedures require the patient not to take anything by mouth
including medications after midnight of the night before the surgery. In this case, H1 and H2 blockers should be
administered intravenously prior to the surgery. The use of corticosteroids, such as prednisone, has also been
suggested although there is no evidence that the short-term use of steroids reduces the ability of mast cells to release
the chemicals contained in their granules. However, corticosteroids may reduce the extent of other inflammatory
reactions that result from mast cell activation.
A tube may be inserted into an artery and attached to a device allowing the anesthesiologist to vigilantly monitor blood
pressure without having to periodically inflate a blood pressure cuff. In addition, a tube is inserted into a vein and
securely taped in place, with intravenous (IV) fluids running to keep the patient well-hydrated in all surgeries involving
general anesthesia or conscious sedation. This tube will also make it possible to immediately administer any emergency
medications that may be needed.

In the operating room, the patient should not be allowed to become either too cold or over-heated. Warm blankets
should be used, and all IV fluids should be warmed before they are given. In addition, there should be a minimum of
noise and bustle around the patient prior to the administration of the anesthetic in order to reduce the possibility of
anxiety-triggered mast cell mediator release.

An emergency situation may arise in which a person with mast cell disease requires immediate surgery. Wearing a
MedicAlert bracelet could be a life-saver if this happens. Inscriptions vary depending upon the patient’s specific needs,
but generally include the patient’s diagnosis and drug sensitivities. Emergency response team members can access
more detailed information 24 hours a day, 7 days a week from the MedicAlert organization by dialling the toll-free
number on the bracelet. MedicAlert is a non-profit organization serving patients world-wide. There are nominal
membership and annual fees with financial assistance available for those in need. For more information, please visit or dial 888-633-4298 within the U.S. or 209-668-3333 from outside the U.S.
Alternatively, there are several companies that manufacture and inscribe medical identification jewellery. These products
are available on the internet and are also carried by some jewellery stores and pharmacies. It may be wise to select
jewellery which provides space for a miniature version of the patient’s medical history (often supplied by the
manufacturer as part of the cost) in addition to the inscription. Although these companies do not have a 24 hour
information center, they do not require membership or annual fees and may be preferable for some patients.
It may also be helpful for mast cell patients to carry with them at all times emergency information, written on their
physician’s letterhead, which contains a list of current medications and other instructions for treatment in the event of
severe symptoms.

Constant attention from the anesthesiologist is required for the safety of a patient with mast cell disease during surgery,
as some of the early symptoms of mast cell mediator release such as flushing, hives, and early signs of obstructed
breathing can be masked by the surgical drapes covering much of the patient’s skin and by the use of an airway tube
during anesthesia.
Should anaphylaxis occur during surgery, the drug thought to be responsible should be discontinued immediately and
epinephrine should be administered. Airway support with 100% oxygen, IV replacement fluids to compensate for dilated
blood vessels, H1 and H2 antihistamines, bronchodilators, and corticosteroids may also be given. Continuous IV
epinephrine and other “vasopressor drugs” may be necessary to keep blood pressure from falling. However, it is
important to keep in mind that not all hypotensive episodes during surgery are due to mast cell degranulation and
anaphylaxis. A serum tryptase level obtained during the hypotensive episode and its comparison with pre-surgery or
“baseline” level may be helpful to determine whether the episode is due to mast cell degranulation.

Records from prior surgeries should be examined and drugs tolerated in those procedures should be preferred if
possible. Prior to the administration of any drugs associated with surgery, it is important that an IV is running, that
epinephrine is available for immediate intramuscular (IM) or IV administration, and that emergency equipment is easily
accessible in case of an adverse reaction.
IV preparations without preservative should be used.
Drugs to avoid include ethanol, dextran, and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and
toradol (unless the patient is already successfully taking a drug in this family), polymyxin B, amphoteracin B, quinine,
dextromethorphan, α-adrenergic blockers, β-adrenergic blockers, and anticholinergic drugs as well as drugs mentioned
in specific categories below.
Local anesthetics – True allergic reactions to local anesthetics resulting from mast cell degranulation are thought to be
rare. Skin testing and graded challenge protocols have been published and may be administered by an allergist prior to
the surgery if questions arise regarding the safe use of a local anesthetic in a patient. If possible, preservative-free local
anesthetic should be used in these tests, as the preservative often present in local anesthetics can cause a mast cell
reaction. In general, local anesthetics in the “ester” group should be avoided. This group includes procaine,
chloroprocaine, tetracaine, and benzocaine. Anaphylactic reactions to local anesthetics in the “amide” group are rare.
This group includes lidocaine, mepivacaine, prilocaine, bupivacaine, levobupivacaine, and ropivacaine.
Muscle relaxants - Muscle relaxants are the most likely group of the anesthetic drugs to cause anaphylaxis.
Succinylcholine, D-tubocurarine, metocurine, doxacurium, atracurium, and mivacurium are more likely to cause a severe
reaction than rocuronium or the so-called nondepolarizing muscle relaxants such as pancuronium or vercuronium. Some
studies have reported increased numbers of anaphylactic reactions to rocuronium, however, so it may not be
appropriate as the first choice for patients with mast cell disease.
Induction drugs - These are medications given to initiate anesthesia. It is rare for mast cell activation to occur in
response to the use of propofol, ketamine, or the benzodiazepine drugs such as midazolam.
Inhaled anesthetics - Sevoflurane is an inhibitor of mast cell activation and is less likely to cause liver damage than
other inhaled anesthetics in this family.
Opiates and opioids - Oral opioid drugs for pain relief may be tolerated by some mast cell disease patients, but their
use should be approached with caution, beginning with very small doses. All drugs in this category are capable of
causing mast cell mediator release.

Surgery for a person with mast cell disease involves exposure to drugs and conditions that may trigger extensive mast
cell degranulation. It should be emphasized that it is often impossible to predict or avoid the risk of adverse events which
may occur in surgery due to the administration of drugs and the procedure itself. The risk can be reduced, though, if the
mast cell disease is brought to the attention of everyone involved in the patient’s care and measures are taken to reduce
the possibility of mast cell mediator release. Careful planning is important, beginning from the time a need for surgery
has been defined and continuing through the immediate pre-operative period, anesthesia, surgery, and recovery. The
choice of drugs is of major importance, and the anesthesiologist, the surgeon, the nursing staff, the patient’s physician,
and the patient should form a working team to ensure that surgery presents the fewest possible dangers for the patient.
Neither The Mastocytosis Society nor the authors intend that this information replace medical advice given by the
patient’s doctor. Patients are encouraged to consult with their doctor regarding medications and procedures related to

Hazards in operative management of patients with systemic mastocytosis; HW Scott Jr, WCV Parris, PC Sandidge, JA
Oates, LJ Roberts II; Annals of Surgery, May 1983;197(5):507-514
Anesthetic management of systemic mastocytosis: experience with 42 cases; WCV Parris, HW Scott, and
BE Smith; Anesthesia and Analgesia (1986)65:S117 (Abstract)
Urticaria Pigmentosa: An anesthetic challenge; Eric P Greenblatt, Linda Chen; Journal of Clinical Anesthesia,
March/April 1990;2:108-115
Mastocytosis: Perioperative considerations; VA Goins; AORN Journal December 1991;54(6):1229-1238
Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique;
A Borgeat and YA Ruetsch; Anesthesia and Analgesia (1998);86:442-444
Treatment of systemic mast cell disorders; AS Worobec; Hematology/Oncology Clinics of North America (June
Treatment of mastocytosis: pharmacologic basis and current concepts; G Marone, G Spadaro, F Granata,
M Triggiani; Leukemia Research, July 2001;25:583-594
Mastocytose: Anesthésie générale par rémifentanil et sévoflurane; L Auvray, B Letourneau, M Freysz; Ann Fr Anesth
Réanim 2001;20:635-638 (article in French)
Mastocytosis: Current concepts in diagnosis and treatment; L Escribano, C Akin, M Castells, A Orfao,
DD Metcalfe; Annuals of Hematology (2002);81:677-690
Anaphylaxis during the perioperative period; DL Hepner and MC Castells; Anesthesia and Analgesia 2003;97:1381-1395
The authors wish to thank Cem Akin MD, PhD, for his review of this article.


Microsoft word - 200000000138_reg_na_en.doc

Material Name: Atactic Polypropylene (APP) Roof Sheets Material Safety Data Sheet ID: 3133 Section 1 - Chemical Product and Company Identification Product Name Atactic Polypropylene Sheets CAS# Mixture (Article) Generic Name Asphalt Coated Polyester Mat & Fiber Glass Mat Formula Hydrocarbon Mixture (Article) Chemical Name: Mixture (Article) Hazard Label RR0

YOUR BENEFITS 10/1/2013 Benefit Summary ASO Choice Plus Greeneview Local Schools Medical Plan 7ME-M UnitedHealthcare and EPC want to help you take control and make the most of your health care benefits. That’s why we provide convenient services to get your health care questions answered quickly and accurately: •® - Take advantage of easy, time-saving on

© 2008-2018 Medical News